Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 11365195
Atypical inhibitors of monoamine transporters; method of making; and use thereof
granted -
US 11364211
Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
granted -
US 11364298
Photosensitizing antibody-fluorophore conjugates
granted -
US 11357839
Brachyury protein, non-poxvirus non-yeast vectors encoding Brachyury protein, and their use
granted -
US 11359204
Chimeric antigen receptors targeting B-cell maturation antigen
granted -
US 11357782
Treprostinil administration by inhalation
granted -
US 11351185
Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
granted -
US 11352435
Anti-CD133 monoclonal antibodies and related compositions and methods
granted -
US 11352410
Anti-KK-LC-1 T cell receptors
granted -
US 11354990
Treatment of kidney diseases associated with elevated AVP
granted -
US 11352365
Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
granted -
US 11345894
Cellular seeding and co-culture of a three dimensional fibroblast construct
granted -
US 11345653
Compositions and methods for reactivating cholinesterases
granted -
US 11344615
Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
granted -
US 11339198
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
granted -
US 11337941
Inhibitors and their uses
granted -
US 11337988
Use of ouabain antagonists to inhibit viral infection
granted -
US 11338032
Methods of preparing anti-human papillomavirus antigen T cells
granted -
US 11338033
Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
granted -
US 11338037
Ultrastable antibody ionic liquids
granted -
US 11337971
Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
granted -
US 11339387
Modified foot-and-mouth disease virus 3C proteases and methods for processing FMDV P1 precursor polypeptide
granted -
US 11332721
Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
granted -
US 11331385
Methods of preparing anti-human papillomavirus antigen T cells
granted -
US 11332722
Development of dengue virus vaccine components
granted -
US 11331370
Combination product for the prevention of sexually transmitted infections
granted -
US 11331286
Inhibitors and their uses
granted -
US 11325965
Single-domain VH H antibodies directed to norovirus GI.1 and GII.4 and their use
granted -
US 11325978
Compositions and methods for treating beta-globinopathies
granted -
US 11324725
Compositions and methods for the inhibition of pruritus
granted -
US 11318196
Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
granted -
US 11318190
Methods and compositions for treating liver disease
granted -
US 11311613
Development of agonist epitopes of the human papillomavirus
granted -
US 11305009
Recombinant virus with diminished latency and methods of using same
granted -
US 11306131
T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage
granted -
US 11306132
HLA class II-restricted T cell receptors against mutated RAS
granted -
US 11306122
Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
granted -
US 11298561
Method of treating multi-drug resistance biofilm using targeted laser and antibiotics
granted -
US 11299546
FLT3-specific chimeric antigen receptors and methods using same
granted -
US 11299476
Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
granted -
US 11299517
Recombinant vaccine against Marek's disease and Newcastle disease
granted -
US 11291712
Bacterial protein compositions and uses thereof
granted -
US 11293010
Methods of producing modified natural killer cells and methods of use
granted -
US 11292758
Compounds and methods for delivery of prostacyclin analogs
granted -
US 11285169
Methods for modulating chemotherapeutic cytotoxicity
granted -
US 11286467
System and method for production of fatty acid ethanolamides
granted -
US 11285178
Fertilized egg isolate and uses thereof
granted -
US 11285204
Tobamovirus-based virus-like particles and vaccines
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory